Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania. more
Time Frame | OBIO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.71% | -3.13% | -0.02% |
1-Month Return | -12.72% | -4.8% | 1.48% |
3-Month Return | -5.98% | -8.46% | 9.63% |
6-Month Return | -32.79% | -2.88% | 13.17% |
1-Year Return | -28.48% | 6.92% | 31.56% |
3-Year Return | -45.63% | 4.63% | 30.19% |
5-Year Return | -53.07% | 42.11% | 93.4% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | 5.70M | (782.00K) | 3.53M | 2.76M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-13.71,"profit":false},{"date":"2022-12-31","value":61.95,"profit":true},{"date":"2023-12-31","value":48.4,"profit":true}] | |
Cost of Revenue | 145.00K | 199.00K | 322.00K | 186.00K | [{"date":"2020-12-31","value":45.03,"profit":true},{"date":"2021-12-31","value":61.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":57.76,"profit":true}] | |
Gross Profit | 5.56M | (981.00K) | 3.21M | 2.57M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-17.65,"profit":false},{"date":"2022-12-31","value":57.77,"profit":true},{"date":"2023-12-31","value":46.31,"profit":true}] | |
Gross Margin | 97.46% | 125.45% | 90.89% | 93.26% | [{"date":"2020-12-31","value":77.69,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":72.45,"profit":true},{"date":"2023-12-31","value":74.34,"profit":true}] | |
Operating Expenses | 24.31M | 20.82M | 35.87M | 54.08M | [{"date":"2020-12-31","value":44.95,"profit":true},{"date":"2021-12-31","value":38.49,"profit":true},{"date":"2022-12-31","value":66.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (18.75M) | (21.80M) | (32.66M) | (51.51M) | [{"date":"2020-12-31","value":-1875200000,"profit":false},{"date":"2021-12-31","value":-2179900000,"profit":false},{"date":"2022-12-31","value":-3265699900,"profit":false},{"date":"2023-12-31","value":-5150600000,"profit":false}] | |
Total Non-Operating Income/Expense | (2.27M) | (2.14M) | (901.00K) | 6.24M | [{"date":"2020-12-31","value":-36.44,"profit":false},{"date":"2021-12-31","value":-34.35,"profit":false},{"date":"2022-12-31","value":-14.45,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | |
Pre-Tax Income | (21.36M) | (23.01M) | (33.61M) | (49.12M) | [{"date":"2020-12-31","value":-2135500000,"profit":false},{"date":"2021-12-31","value":-2301400000,"profit":false},{"date":"2022-12-31","value":-3360800000,"profit":false},{"date":"2023-12-31","value":-4912000000,"profit":false}] | |
Income Taxes | 2.60M | 927.00K | (222.00K) | 119.11K | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":35.61,"profit":true},{"date":"2022-12-31","value":-8.53,"profit":false},{"date":"2023-12-31","value":4.58,"profit":true}] | |
Income After Taxes | (23.96M) | (23.94M) | (33.39M) | (49.24M) | [{"date":"2020-12-31","value":-2395800000,"profit":false},{"date":"2021-12-31","value":-2394100000,"profit":false},{"date":"2022-12-31","value":-3338600100,"profit":false},{"date":"2023-12-31","value":-4923910500,"profit":false}] | |
Income From Continuous Operations | (21.36M) | (23.01M) | (33.61M) | (49.12M) | [{"date":"2020-12-31","value":-2135500000,"profit":false},{"date":"2021-12-31","value":-2301400000,"profit":false},{"date":"2022-12-31","value":-3360800000,"profit":false},{"date":"2023-12-31","value":-4912000000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (21.36M) | (23.01M) | (33.61M) | (49.12M) | [{"date":"2020-12-31","value":-2135500000,"profit":false},{"date":"2021-12-31","value":-2301400000,"profit":false},{"date":"2022-12-31","value":-3360800000,"profit":false},{"date":"2023-12-31","value":-4912000000,"profit":false}] | |
EPS (Diluted) | (0.01) | (0.02) | (0.19) | (1.50) | [{"date":"2020-12-31","value":-1.32,"profit":false},{"date":"2021-12-31","value":-2.32,"profit":false},{"date":"2022-12-31","value":-19,"profit":false},{"date":"2023-12-31","value":-150,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
OBIO | |
---|---|
Cash Ratio | 4.13 |
Current Ratio | 4.23 |
Quick Ratio | 4.21 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
OBIO | |
---|---|
ROA (LTM) | -39.20% |
ROE (LTM) | -91.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
OBIO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.39 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.61 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
OBIO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 80.31 |
P/B | 4.60 |
Price/FCF | NM |
EV/R | 55.72 |
EV/Ebitda | NM |
Orchestra BioMed Holdings Inc. (OBIO) share price today is $5.39
Yes, Indians can buy shares of Orchestra BioMed Holdings Inc. (OBIO) on Vested. To buy Orchestra BioMed Holdings Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OBIO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Orchestra BioMed Holdings Inc. (OBIO) via the Vested app. You can start investing in Orchestra BioMed Holdings Inc. (OBIO) with a minimum investment of $1.
You can invest in shares of Orchestra BioMed Holdings Inc. (OBIO) via Vested in three simple steps:
The 52-week high price of Orchestra BioMed Holdings Inc. (OBIO) is $11.69. The 52-week low price of Orchestra BioMed Holdings Inc. (OBIO) is $4.22.
The price-to-earnings (P/E) ratio of Orchestra BioMed Holdings Inc. (OBIO) is
The price-to-book (P/B) ratio of Orchestra BioMed Holdings Inc. (OBIO) is 4.60
The dividend yield of Orchestra BioMed Holdings Inc. (OBIO) is 0.00%
The market capitalization of Orchestra BioMed Holdings Inc. (OBIO) is $212.57M
The stock symbol (or ticker) of Orchestra BioMed Holdings Inc. is OBIO